tirzepatide vs semaglutide
This is the cleanest way to understand the incretin classes: semaglutide is a single-receptor agonist, tirzepatide is a dual-receptor agonist. The comparison is about how many incretin receptors each engages — and where the research record sits. Veyvora supplies tirzepatide (and the triple agonist retatrutide); we do not stock semaglutide.
single agonist vs dual agonist
Semaglutide is a single GLP-1 receptor agonist — it engages one incretin receptor, the most-studied one in glucose-regulation and appetite research. Tirzepatide is a dual GIP/GLP-1 co-agonist: one molecule engaging two incretin receptors. That extra GIP arm is the whole difference between the two classes.
why the receptor count is the axis
Adding the GIP receptor doesn't make tirzepatide "a better semaglutide" — it makes it a different research tool, studied for what two incretin arms do together that one does not. Semaglutide's single-agonist record is longer and deeper; the dual-agonist class is newer. Which is the right comparator depends entirely on the receptor question being asked.
where the triple agonist fits
The progression is single → dual → triple. Retatrutide adds a third arm, the glucagon receptor, on top of tirzepatide's dual profile. For the dual-vs-triple step, see retatrutide vs tirzepatide.
what Veyvora supplies
We stock tirzepatide and retatrutide as research pens, each pre-filled and independently assayed with a batch-specific certificate of analysis. We do not supply semaglutide — it appears here only as the single-agonist reference point. See how to read a COA.
research use only
Both compounds are supplied strictly for in-vitro and laboratory research use only — not medicines, not for human or veterinary consumption. Nothing here is dosing, medical or treatment guidance.
the research pens
Pre-filled, batch-numbered and independently assayed. Save one to your list and we'll email you the moment it's available in your country.
